One key difference between these studies is that patients with all stages of CRC (TNM I–IV) were included in the cohort studied by Lundberg et al. [19] and in the majority of cohorts analyzed by Song et al. [21], whereas we assessed the prognostic value of high SOX2 density in stage II and stage III patients separately. The gene discussed is SOX2; the disease is colorectal carcinoma.